D.E. Shaw & Co
PGNX

D.E. Shaw & Co’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

D.E. Shaw & Co’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-12,225
Closed -$46K – 4368
2020
Q1 		$46K Sell
12,225
-22,209
-64% -$95.7K ﹤0.01% 3838
2019
Q4 		$175K Buy
+34,434
New +$182K ﹤0.01% 3830
2016
Q2 		– Sell
-11,552
Closed -$50K – 3615
2016
Q1 		$50K Sell
11,552
-2,707
-19% -$12.1K ﹤0.01% 3334
2015
Q4 		$87K Sell
14,259
-2,041
-13% -$13.4K ﹤0.01% 3680
2015
Q3 		$93K Sell
16,300
-3,196
-16% -$24.5K ﹤0.01% 3619
2015
Q2 		$145K Sell
19,496
-55,238
-74% -$334K ﹤0.01% 3620
2015
Q1 		$447K Sell
74,734
-141,901
-66% -$893K ﹤0.01% 3114
2014
Q4 		$1.64M Buy
216,635
+155,022
+252% +$928K ﹤0.01% 2431
2014
Q3 		$320K Buy
+61,613
New +$307K ﹤0.01% 3654
2014
Q2 		– Sell
-11,689
Closed -$48K – 4657
2014
Q1 		$48K Sell
11,689
-395,074
-97% -$2.02M ﹤0.01% 4203
2013
Q4 		$2.17M Sell
406,763
-168,331
-29% -$741K ﹤0.01% 2457
2013
Q3 		$2.89M Buy
575,094
+71,001
+14% +$385K ﹤0.01% 2107
2013
Q2 		$2.25M Buy
+504,093
New +$2.26M ﹤0.01% 2010

Other funds holding PGNX

ECM
Everence Capital Management Goshen, Indiana $1.64B AUM 26.46% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $49.2B AUM 29.3% 1-Year Est. Return
Daiwa Securities Group
Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

D.E. Shaw & Co's PGNX Position: Q2 2020 in Review

D.E. Shaw & Co sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 12,225 shares — an estimated $46K sold.

D.E. Shaw & Co first reported a position in PGNX in Q2 2013 and held it in 13 quarters. The position peaked at $2.89M in Q3 2013. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.

  • D.E. Shaw & Co reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
  • D.E. Shaw & Co sold 12,225 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $46K.
  • D.E. Shaw & Co first reported a position in Progenics Pharmaceuticals Inc in Q2 2013 and held it in 13 quarters.
  • D.E. Shaw & Co's Progenics Pharmaceuticals Inc position peaked at $2.89M in Q3 2013.
  • 3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.

Based on D.E. Shaw & Co's 13F filing for Q2 2020, filed 14 Aug 2020.